Innovative Industrial Properties, Inc. IIPR Life Science Portfolio Segment: — Segment Total Assets:

Other segment segments

Cannabis Portfolio Segment:

$2.15B—

Similar metrics at other companies

BIOLife Science — Total Assets

$301.7M-2.1%

ASHLife Sciences — Total Assets

$1.46B-22.4%

TMOLife Sciences Solutions — Segment assets

$3.49B+15.6%

DHRLife Sciences — Identifiable assets

$22.87B—

GLW

GLWLife Sciences and Emerging Growth Businesses — Segment assets

$1.42B—

TMOLaboratory Products and Biopharma Services — Segment assets

$6.92B+7.0%

Other financials

Income statement

See full

Revenue$69.0M-3.8%

Operating income$32.9M-3.1%

Net income$32.8M+5.6%

EPS (diluted)$1.02-1.0%

Balance sheet

See full

Cash & equivalents$89.1M-30.4%

Total debt$570.0K-99.8%

Total equity$1.9B-1.4%

Total assets$2.4B+1.8%

Cash flow

See full

Operating cash flow$56.0M+3.3%

Valuation

See full

Market cap$1.76B-7.9%

P/E14.7×+2.2×

P/S6.7×+0.4×

Profitability

See full

Operating margin46.8%-5.8pp

Net margin45.6%-4.7pp

Returns & leverage

See full

Return on equity6.3%-1.6pp

Debt / equity0×-0.1×

Where this comes from

Reported directly by Innovative Industrial Properties, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Innovative Industrial Properties, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovative Industrial Properties, Inc.'s life science portfolio segment: — segment total assets:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Innovative Industrial Properties, Inc.'s life science portfolio segment: — segment total assets:?: Innovative Industrial Properties, Inc. (IIPR) reported life science portfolio segment: — segment total assets: of $153.98M in Q1 2026.
What does life science portfolio segment: — segment total assets: mean?: This metric represents the aggregate book value of all real estate holdings and related capital investments categorized under the life science portfolio segment. It quantifies the scale and capital deployment dedicated to this specific business vertical. Tracking this figure allows stakeholders to monitor the growth and relative weight of the life science segment within the company's total asset base.